CHASE THERAPEUTICS
Chase Therapeutics is an early-stage, product-based specialty pharmaceutical company focused on the development of better treatments for brain disease.
CHASE THERAPEUTICS
Industry:
Medical Medical Device Pharmaceutical Therapeutics
Founded:
2017-01-01
Address:
Washington, District Of Columbia, United States
Country:
United States
Website Url:
http://www.chasetherapeutics.com
Total Employee:
101+
Status:
Active
Contact:
(202) 223-7002
Total Funding:
25.3 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Apache Wordpress Plugins Sitelinks Search Box
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Blade Therapeutics
Blade Therapeutics is a discovery stage drug development company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Portal Instruments
Portal Instruments is an early stage company that offers medical device.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Synthon Chiragenics Corp.
Synthon Chiragenics Corp. is a world-leader in carbohydrate-based chiral technology for pharmaceuticals
Vetsource
Vetsource provides comprehensive solutions to those who care for pets - veterinarians and pet owners.
Current Advisors List
Founder
Investors List
China Link Capital
China Link Capital investment in Series B - Chase Therapeutics
Revolution
Revolution investment in Venture Round - Chase Therapeutics
Revolution’s Rise of the Rest Seed Fund
Revolution’s Rise of the Rest Seed Fund investment in Venture Round - Chase Therapeutics
Official Site Inspections
http://www.chasetherapeutics.com Semrush global rank: 6.16 M Semrush visits lastest month: 1.31 K
- Host name: s277.sureserver.com
- IP address: 192.252.144.27
- Location: Waltham United States
- Latitude: 42.3972
- Longitude: -71.2434
- Metro Code: 506
- Timezone: America/New_York
- Postal: 02451
More informations about "Chase Therapeutics"
Overview - Chase Therapeutics
[email protected]. Home; Overview; Management. Board of Directors; Products. Disease Focus; Product Discovery; Partnering; Financing; Contact; Overview. Chase Therapeutics > Overview. About Chase …See details»
Management - Chase Therapeutics
Board Chair. Kathleen Clarence-Smith, MD, PhD, is a neurologist whose career has been dedicated to identifying, selecting for development new pharmaceuticals, and shepherding …See details»
Chase Therapeutics - Crunchbase Company Profile & Funding
Chase Therapeutics is an early-stage, product-based specialty pharmaceutical company focused on the development of better treatments for brain disease.See details»
Chase Theraputics Company Profile | Management and Employees …
Www.chasetherapeutics.com . Contact Information. Headquarters. 1825 K St NW Ste 510, Washington, District of Columbia, 20006, United States (202) 568-8831. Chase Theraputics …See details»
Chase Therapeutics Corp.: Drug pipelines, Patents, Clinical trials ...
Aug 2, 2023 Explore Chase Therapeutics Corp. with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 2 news, Disease Domain:Nervous System Diseases ...See details»
Chase Theraputics - Overview, News & Similar companies
Chase Theraputics contact info: Phone number: (202) 568-8831 Website: www.chasetherapeutics.com What does Chase Theraputics do? Chase Therapeutics is an …See details»
Chase Therapeutics Corporation - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Chase Therapeutics Corporation of Washington, DC. Get the latest business insights from Dun & …See details»
Chase Therapeutics Corporation Company Profile -Sales, Contacts ...
Chase Therapeutics Corporation is in the Pharmaceuticals industry within the Wholesale Trade - Nondurable Goods sector and has been in business for approximately (2) years.See details»
CHASE THERAPEUTICS - The Org
Chase Therapeutics is an early-stage, product-based specialty pharmaceutical company focused on the development of better treatments for brain disease.See details»
Chase Therapeutics - Company Profile - Tracxn
Oct 24, 2024 Chase Therapeutics - Developer of drugs for neurodegenerative disorders. Raised a total funding of $30.9M over 4 rounds from 2 investors. Founded by Thomas Chase and …See details»
Chase Therapeutics - VentureRadar
Website: http://www.chasetherapeutics.com/ Chase Therapeutics is an early-stage, product-based specialty pharmaceutical company focused on the development of better ...See details»
Chase Therapeutics - PitchBook
Chase Therapeutics General Information Description. Operator of a pharmaceutical company intended to develop drugs for the treatment of brain disease. The company's novel …See details»
Partnering - Chase Therapeutics
Chase Therapeutics essentially operates as a virtual organization. The company finds resource support with individual investigators and research institutions as well as with pharmaceutical …See details»
Working At Chase Therapeutics: Company Overview and Culture
Mar 14, 2024 Organization Type. Private. Chase Therapeutics is an early-stage, product-based specialty pharmaceutical company focused on the development of better treatments for brain …See details»
Chase Therapeutics - Craft
Chase Therapeutics has 1 employees at their 1 location and $5.3 m in total funding,. See insights on Chase Therapeutics including office locations, competitors, revenue, financials, executives, …See details»
Financing - Chase Therapeutics
Chase Therapeutics raised Series A-1 equity financing from The Brain Trust Accelerator Fund II in November 2017 to support Phase 1 clinical trial and related drug development activities.See details»
Chase, after selling last biotech to Allergan, gets cash to start ...
Oct 20, 2021 Chase Therapeutics is heading into pivotal trials. Armed with $20 million, the biotech plans to start phase 3 clinical trials of candidates based on an old Boehringer …See details»
Product Discovery and Development - Chase Therapeutics
Chase Therapeutics’ drug development pipeline currently holds promising examples of our unique approach to products targeting both the palliative and neuroprotective treatment of Parkinson’s …See details»
Disease Focus - Chase Therapeutics
Major depressive disorder afflicts over 200 million people worldwide. Characterized by a persistently depressed mood, major depressive disorder is often associated with feelings of …See details»